Consumer preference for dinoprostone vaginal gel using stated preference discrete choice modelling.
OBJECTIVE
To assess consumer preference for two methods of induction of labour using stated preference discrete choice modelling. The methods of induction were artificial rupture of the membranes (ARM) plus oxytocin and dinoprostone (prostaglandin E(2)) vaginal gel, followed by oxytocin if necessary.


METHODS
Consumer preference was measured in terms of willingness to pay for each of the attributes. These attributes were the method of administration, place of care, length of time from induction to delivery, need for epidural anaesthetic, type of delivery and cost. Levels were assigned to each of the attributes. Pregnant women attending a public hospital antenatal clinic were asked to read a description of the two methods and then to choose between them in 18 different scenarios in which the levels of the attributes were varied.


RESULTS
Women were willing to pay 11 Australian dollars for a 1% reduction in the chance of needing oxytocin as well as the gel and 55 Australian dollars for every 1 hour reduction in the length of time from induction to delivery. For a 1% reduction in the chance of needing an epidural anaesthetic or Caesarean section, women expressed a willingness to pay of 20 Australian dollars and 90 Australian dollars, respectively. All estimates were obtained in 1998 and expressed in Australian dollars (1 Australian dollar = 0.63 US dollars).


CONCLUSIONS
Women valued the less invasive method of administration of the gel and the associated greater freedom of movement during labour. However, they valued the shorter time from induction to delivery associated with ARM plus oxytocin more highly. A policy which allows women access to the gel for up to two doses would accommodate this consumer preference.
Taylor
Susan
S
Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia. suet@pharm.usyd.edu.au
Armour
Carol
C
D000293:Adolescent; D000328:Adult; D001315:Australia; D002755:Choice Behavior; D015232:Dinoprostone / Q000008:administration & dosage*; D005260:Female; D005382:Financing, Personal; D005782:Gels; D006801:Humans; D007751:Labor, Induced / Q000191:economics / Q000379:methods*; D010120:Oxytocics / Q000008:administration & dosage*; D017060:Patient Satisfaction / Q000191:economics* / Q000706:statistics & numerical data; D011247:Pregnancy; D011795:Surveys and Questionnaires; D013997:Time Factors
D005782:Gels; D010120:Oxytocics; D015232:Dinoprostone